Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Talks Drug Safety With China, But Visas Still Elusive For Staff

This article was originally published in The Tan Sheet

Executive Summary

The agency is unable to place more inspectors in China even as Howard Sklamberg, deputy commissioner for global regulatory operations and policy, visits Beijing.

You may also be interested in...



How FDA Plans To Stop Worrying And Love Globalization

New deputy commissioner Howard Sklamberg tells “The Pink Sheet” that globalization of the drug supply eventually will become more commonplace, and ideally less of a concern, for American consumers.

FDA Inspection Growth In China Stymied By Visa Issues

The agency is waiting for approval to locate 10 new drug inspectors in China.

FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production

FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel